US Patent

US10596162 — Method for treating gefitinib resistant cancer

Method of Use · Assigned to Wyeth LLC · Expires 2026-02-02 · 0y expired

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating cancer that has become resistant to the drugs gefitinib and erlotinib.

USPTO Abstract

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3338 — Vizimpro
U-3338 — Vizimpro
U-3338 — Vizimpro

Patent Metadata

Patent number
US10596162
Jurisdiction
US
Classification
Method of Use
Expires
2026-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.